ATAC trial: reporting interim results is not helpful

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7402.1329-b (Published 12 June 2003) Cite this as: BMJ 2003;326:1329
  1. Heather Goodare (hm.goodare@virgin.net), chair,
  2. Clare Dimmer (clare@solvatec.demon.uk), secretary,
  3. Kathy Page (kathypage@btinternet.com), treasurer
  1. Breast UK (Breast-cancer Research Ethics and Advocacy Strategy), Horsham, West Sussex RH13 6DF
  2. Breast UK Waterlooville, Hants PO7 6LA
  3. Breast UK Lower Layham, Suffolk IP7 5NA

    EDITOR—We should like to raise some concerns about the ATAC (arimidex, tamoxifen alone or in combination) trial, which was reported on in the Lancet after only half the time stipulated in the protocol (2.5 years instead of 5).1 Ravdin has raised important points: “Early reporting rules can powerfully …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription